Precipio (PRPO) Competitors

Accelerate Diagnostics (NASDAQ:AXDX) and Precipio (NASDAQ:PRPO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.

Does the media prefer AXDX or PRPO?

In the previous week, Accelerate Diagnostics had 1 more articles in the media than Precipio. MarketBeat recorded 4 mentions for Accelerate Diagnostics and 3 mentions for Precipio. Accelerate Diagnostics' average media sentiment score of 1.44 beat Precipio's score of 1.33 indicating that Accelerate Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Accelerate Diagnostics	Positive
Precipio	Positive

Which has stronger earnings & valuation, AXDX or PRPO?

Precipio has higher revenue and earnings than Accelerate Diagnostics. Precipio is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accelerate Diagnostics	$12.06M	2.74	-$61.62M	-$2.86	-0.46
Precipio	$15.20M	0.61	-$5.85M	-$1.83	-3.45

Is AXDX or PRPO more profitable?

Precipio has a net margin of -17.23% compared to Accelerate Diagnostics' net margin of -471.83%. Accelerate Diagnostics' return on equity of 0.00% beat Precipio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accelerate Diagnostics	-471.83%	N/A	-191.66%
Precipio	-17.23%	-34.01%	-25.27%

Which has more volatility & risk, AXDX or PRPO?

Accelerate Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Precipio has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of AXDX or PRPO?

17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 10.5% of Precipio shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 13.3% of Precipio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Do analysts rate AXDX or PRPO?

Accelerate Diagnostics currently has a consensus target price of $1.00, indicating a potential downside of 24.24%. Given Accelerate Diagnostics' stronger consensus rating and higher probable upside, research analysts clearly believe Accelerate Diagnostics is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accelerate Diagnostics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Precipio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the MarketBeat Community prefer AXDX or PRPO?

Accelerate Diagnostics received 83 more outperform votes than Precipio when rated by MarketBeat users. However, 73.32% of users gave Precipio an outperform vote while only 59.87% of users gave Accelerate Diagnostics an outperform vote.

Company	Underperform	Outperform
Accelerate Diagnostics	Outperform Votes 355 59.87%	Underperform Votes 238 40.13%
Precipio	Outperform Votes 272 73.32%	Underperform Votes 99 26.68%

Summary

Accelerate Diagnostics beats Precipio on 12 of the 19 factors compared between the two stocks.